Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Coronavirus company news summary – Pfizer/BioNTech to supply 100 million more doses of Comirnaty to EU – Adagio raises $336m for development of Covid-19 antibody treatment

20 Apr 2021 (Last Updated April 20th, 2021 09:59)

Pfizer and BioNTech will supply an additional 100 million doses of their Covid-19 vaccine, Comirnaty, to the European Union (EU) member states in 2021. The is a result of the European Commission’s decision to activate its option of purchasing an additional 100 million doses under its expanded advanced purchase agreement signed on 17 February 2021. This brings the total number of Comirnaty doses to be supplied to the EU to 600 million.

Biotechnology company Adagio Therapeutics has completed a $336m Series C financing led by RA Capital Management. The funding is expected to support the advancement of ADG20, an antibody therapy for the treatment and prevention of Covid-19 and other future coronaviruses. Pre-clinical data suggests the drug candidate achieves complete neutralisation of the SARS-CoV-2 virus and all known variants of concern. Adagio has begun a Phase I study of ADG20 in healthy volunteers, and a pivotal Phase I/II/III trial in high-risk individuals with mild or moderate Covid-19.

The Russian Direct Investment Fund (RDIF) and Hualan Biological Bacterin, a subsidiary of Hualan Biological Engineering, are collaborating on the production of more than 100 million doses of the Sputnik V per year in China, enough to vaccinate 50 million people. Sputnik V has been approved across 60 countries globally, and has an efficacy rate of 91.6%.